CYP2D6 and breast carcinoma: In a study conducted on 92 Turkish breast cancer patients, CYP2D6 gene polymorphisms were classified as follows: 2.17% poor metabolizer, 11.95% intermediate metabolizer, 80.43% normal metabolizer, and 5.43% ultra-rapid metabolizer [23].